Join the club for FREE to access the whole archive and other member benefits.

Owlstone Medical

Company focused to development of non-invasive diagnostics for cancer and inflammatory diseases.

Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.

The company’s Breath Biopsy® platform has introduced a new diagnostic modality making it possible to discover novel non-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award winning ReCIVA Breath Sampler ensures reliable collection of breath samples. The volatile organic compounds (VOCs) present in breath are analyzed using proven microchip chemical sensor technology (FAIMS) to detect biomarkers of disease.

The Breath Biopsy platform can be used in clinical diagnostics and precision medicine with applications in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and more lives can be saved.

Visit website:




Details last updated 09-Jan-2020

People at Owlstone Medical

Morad K. Nakhleh

Lead Breath Biomarker Scientist at Owlstone Medical.

Billy Boyle

Co-Founder and CEO at Owlstone Medical Ltd.

Owlstone Medical News

Owlstone Medical raised $58M to advance its breath biopsy technology

FierceBiotech - 07-Sep-2021

Developing painless tests to detect lung cancer, liver diseases, respiratory diseases, and gut health


Cancer breathalyser starts clinical trial for wide range of cancers

Guardian - 03-Jan-2019

VOCs in breath captured by mask sent to lab for diagnosis - avoids invasive tests


Lung cancer breath test trialled

BBC - 14-Feb-2015

Clinically trials planned for this year

Topics mentioned on this page:
Digital Health, Medical Technology